Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia Clinical research trials and A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia. A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia clinical trial. Subjects often receive the most expert healthcare possible for their A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.

Home > "A" Clinical Trials Conditions > A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia

A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia



A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia

For Condition: Pneumonia, Pneumocystis carinii,HIV Infections
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: To evaluate and compare 3 anti-pneumocystis regimens plus zidovudine (AZT) in persons with advanced HIV disease and T4 cell count < 200 cells/mm3. To establish the range of pentamidine (PEN) deposition in AIDS patients participating in ACTG 021 and ACTG 081. To identify factors (breathing pattern, pulmonary function) that may be important in affecting the actual dose delivered to a given patient. The specific system that is used to deliver PEN to the lungs may determine whether a therapeutically effective dose is attained in the lungs. Therefore, this study will establish the amount of PEN that is deposited in the lungs of patients enrolled in protocols ACTG 021 and ACTG 081, who are being treated with PEN administered from the Marquest Respirgard II nebulizer.
Details: The specific system that is used to deliver PEN to the lungs may determine whether a therapeutically effective dose is attained in the lungs. Therefore, this study will establish the amount of PEN that is deposited in the lungs of patients enrolled in protocols ACTG 021 and ACTG 081, who are being treated with PEN administered from the Marquest Respirgard II nebulizer. Approximately 4 weeks after patients in ACTG 021 and ACTG 081 have begun PEN aerosol therapy for the prevention of PCP, patients undergo the first radioactive aerosol study. The patient inhales a mist while sitting with his/her back against a gamma camera. The resulting picture outlines the lungs. This mist contains a single dose of PEN mixed with a small amount of radioactivity (99m-technetium ertechnetate). The gamma camera determines where the particles deposit in the lungs. The radioactivity exposure is equivalent to a typical xray of the ribs. This procedure takes about 45 minutes; 6 hours later another 30-minute gamma camera image is obtained. Blood is withdrawn to measure the blood level of PEN as done in ACTG 021 and ACTG 081. The entire procedure is repeated near the end of the prophylactic schedule (about 10-12 months after the start of aerosol PEN treatments).
Eligibility:
Study Type:  Interventional, Treatment, Placebo Control, Pharmacokinetics Study
Minimum Age/Maximum Age: 12 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Treatment: Allowed: - Local radiation for Kaposi's sarcoma. Patients who successfully completed a course of study therapy for acute Pneumocystis carinii pneumonia (PCP) and who met the inclusion criteria for Protocol ACTG 021 or ACTG 081 and were randomized to the aerosolized pentamidine arm. - Patients who are currently receiving aerosolized pentamidine as prophylactic therapy for PCP. Exclusion Criteria The following patients are excluded: - Those enrolled in ACTG 021 and randomized to the oral prophylaxis arm. - Those enrolled in ACTG 081 and randomized to the trimethoprim / sulfamethoxazole and dapsone arms. Prior Treatment: Excluded within 2 weeks of study entry: - Transfusions of blood or red blood cells. Co-Existing Condition: - Significant adverse effects. Active substance abuse.
Total Enrollment: 20

Location and Contact Information:

Overall Study Official:
GCSmaldone,  Study Chair, 

SUNY - Stony Brook
Stony Brook,  New York,  117948153
United States
 


Additional Information:
Study ID Numbers:  ACTG 079; 
Study Start Date: 
Record last reviewed: February 1992
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001003

Other Hiv Infections Studies:
1. A Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen

2. Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children

3. Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults

4. Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients with Drug-resistant HIV

5. A Study to Compare Two Anti-HIV Drug Combinations

Related Studies:

Other HIV Infections Clinical Trials
Other New York Clinical Trials
Other Stony Brook Clinical Trials

A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia
Modify your Search

  Other HIV Infections Clinical Trials
  Other New York Clinical Trials
  Other Stony Brook Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103